OKUR Stock Summary and Trading Ideas (Onkure Therapeutics - Class A | NASDAQ:OKUR)

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Ka. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

Onkure Therapeutics - Class A trades on the NASDAQ stock market under the symbol OKUR.

As of October 9, 2026, OKUR stock price climbed to $2.41 with 601,753 million shares trading.

OKUR has a beta of 1.01, meaning it tends to be more sensitive to market movements. OKUR has a correlation of 0.03 to the broad based SPY ETF.

OKUR has a market cap of $97.60 million. This is considered a Micro Cap stock.

Last quarter Onkure Therapeutics - Class A reported $0 in Revenue and -$.31 earnings per share. This fell short of revenue expectation by $-200,000 and exceeded earnings estimates by $.31.

The top ETF exchange traded funds that OKUR belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.

OKUR has underperformed the market in the last year with a price return of -23.0% while the SPY ETF gained +17.1%. OKUR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.0% and -16.9%, respectively, while the SPY returned +3.8% and +0.9%, respectively.

OKUR support price is $2.17 and resistance is $2.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OKUR shares will trade within this expected range on the day.